-
Roche Alecensa gets USFDA nod for ALK-positive early-stage lung cancer
20 Apr 2024 09:27 GMT
… the European Medicines Agency.
Lung cancer is one of the leading … non-small cell lung cancer (NSCLC) and small-cell lung cancer. NSCLC is … despite adjuvant chemotherapy. Treating lung cancer early, before it has … Atezolizumab, Lenvatinib, and Sorafenib Study
-
CDSCO Panel Approves Roche's Protocol Amendment Proposal For Anti-cancer Drug Atezolizumab, Lenvatinib, and Sorafenib Study
14 Apr 2024 16:10 GMT
… Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in … lenvatinib or sorafenib versus lenvatinib or sorafenib alone in … prevent non-small cell lung cancer (NSCLC) from coming … potent antiangiogenic properties.
Sorafenib is used to treat …
-
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
07 Feb 2024 12:27 GMT
… cancers to date, including lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading cause … previously treated with sorafenib. This indication is … lung cancer; Checkmate 816-neoadjuvant non-small cell lung cancer, …
-
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
26 Apr 2024 11:14 GMT
… carcinoma, non-small cell lung cancer, malignant pleural mesothelioma, … positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … previously treated with sorafenib. This indication is … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …
-
Research Progress of Long Non-Coding RNA in Tumor Drug Resistance: A New Paradigm
26 Apr 2024 08:13 GMT
… of death after lung cancer. The first-line … Lung Cancer
Lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer … after treatment with sorafenib.52 LncRNA TUC338 … -induced PVT1 promotes lung cancer chemoresistance to cisplatin …
-
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
11 Dec 2023 11:56 GMT
… -small cell lung cancer.”
“Addressing lung cancer reflects the … rank=1.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
07 Dec 2023 12:21 GMT
… lung cancer.”
Merck has an extensive clinical development program in lung cancer … toxicity.
About lung cancer
Lung cancer is the … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … treated with sorafenib. This indication …
-
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
07 Dec 2023 11:36 GMT
… non-small cell lung cancer (NSCLC) with … docetaxel alone.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
25 Apr 2024 11:21 GMT
… to IIIB non-small cell lung cancer (NSCLC). The FDA assigned a … investigator's choice of sorafenib or lenvatinib at a pre … its pipeline and added commercialized lung cancer medicine Krazati to its oncology …
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
20 Oct 2023 12:17 GMT
… in certain advanced lung cancers, these overall … were identified.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib.
This indication is …